Pierre Meulien
Director/Board Member presso The Innovative Medicines Initiative
Profilo
Dr. Pierre Meulien is a Director at Ontario Genomics Institute (Private Equity).
Dr. Meulien has served as an ex officio observer on OGI's Board of Directors since 2010.
He became President and CEO of Genome Canada in 2010.
Previously, Dr. Meulien was Chief Scientific Officer for Genome British Columbia (Genome BC), where he promoted the organization's ongoing scientific strategy, focusing on genomics, proteomics and bioinformatics within the larger realm of biotechnology and life sciences sector.
He was also pivotal in developing an international strategy that resulted in partnerships with the European Union, Chile, Australia and Norway.
Prior to Genome BC, Dr. Meulien was the founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland) and held international leadership roles, including Senior Vice President of R&D with Aventis Pasteur (now sanofi pasteur, a division of sanofi-aventis, one of the top ten pharma companies worldwide) in Toronto, Director of Research for Aventis Pasteur in Lyon, France, and as a research scientist and member of the management team with Transgene, a biotechnology company in Strasbourg.
Dr. Meulien's received his PhD in Molecular Biology from the University of Edinburgh and was a post-doctoral fellow at the Institut Pasteur in Paris.
Posizioni attive di Pierre Meulien
| Società | Posizione | Inizio |
|---|---|---|
The Innovative Medicines Initiative
 The Innovative Medicines Initiative Drugstore ChainsRetail Trade The Innovative Medicines Initiative is a public-private partnership that aims to accelerate the development of better and safer medicines for patients. The private company is based in Brussels, Belgium and has subsidiaries in Sweden. The Programme Office, led by the Executive Director, manages the day-to-day operations of the initiative. The initiative recognizes the importance of communication and provides accessible tools generated by their projects to help scientists in their research efforts. The Belgian company was founded by J. Kenneth Charles Knowles. | Director/Board Member | 15/09/2015 |
Precedenti posizioni note di Pierre Meulien
| Società | Posizione | Fine |
|---|---|---|
Genome British Columbia
 Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 01/01/2010 |
| Clinical Research Development Ireland | Founder | 01/01/2007 |
Ontario Genomics Institute (Private Equity)
 Ontario Genomics Institute (Private Equity) Investment ManagersFinance Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London. | Corporate Officer/Principal | - |
Génome Québec, Inc.
 Génome Québec, Inc. Miscellaneous Commercial ServicesCommercial Services Génome Québec, Inc. develops genomics and DNA in Quebec. It helps to accelerate the discovery of new applications for genomics and DNA in strategic areas such as human health, forestry and the environment. The company was founded in 2000 and is headquartered in Montreal, Canada. | Director/Board Member | - |
| TRANSGENE | Corporate Officer/Principal | - |
Formazione di Pierre Meulien
| The University of Liverpool | Undergraduate Degree |
| The University of Edinburgh | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| TRANSGENE | Health Technology |
| Aziende private | 8 |
|---|---|
| Aventis Pasteur Sa | Health Technology |
Genome Canada
 Genome Canada Miscellaneous Commercial ServicesCommercial Services Genome Canada provides genomic research services. It connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation,and translates discoveries into applications, new technologies, societal impacts and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries and aquaculture, energy, mining, and the environment. The company was founded in 2000 and is headquartered in Ottawa, Canada. | Commercial Services |
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Commercial Services |
Génome Québec, Inc.
Génome Québec, Inc. Miscellaneous Commercial ServicesCommercial Services Génome Québec, Inc. develops genomics and DNA in Quebec. It helps to accelerate the discovery of new applications for genomics and DNA in strategic areas such as human health, forestry and the environment. The company was founded in 2000 and is headquartered in Montreal, Canada. | Commercial Services |
| Aventis Pasteur Ltd. | |
| Clinical Research Development Ireland | |
The Innovative Medicines Initiative
The Innovative Medicines Initiative Drugstore ChainsRetail Trade The Innovative Medicines Initiative is a public-private partnership that aims to accelerate the development of better and safer medicines for patients. The private company is based in Brussels, Belgium and has subsidiaries in Sweden. The Programme Office, led by the Executive Director, manages the day-to-day operations of the initiative. The initiative recognizes the importance of communication and provides accessible tools generated by their projects to help scientists in their research efforts. The Belgian company was founded by J. Kenneth Charles Knowles. | Retail Trade |
Ontario Genomics Institute (Private Equity)
Ontario Genomics Institute (Private Equity) Investment ManagersFinance Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London. | Finance |
- Borsa valori
- Insiders
- Pierre Meulien
